Affibody

https://www.affibody.com/

Last activity: 23.06.2026

Active - Reference to Affibody AB

Categories: BiotechClinicalStageOncologyPharmaceuticalsRadiotherapy

Mentions

Overview

Location

Sweden

Employees

11-50

Founded date

1998

Mentions in press and media 22

Reviews 0

FAQ about Affibody

When was Affibody founded?

Affibody was founded in 1998.

What has the press written about Affibody?

Parsers VC has collected 22 articles mentioning Affibody, among them “Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177” (Feb 19, 2026) and “Affibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement” (Feb 18, 2026).

Is Affibody still active?

Yes, Affibody is active; its latest activity on Parsers VC dates from Jun 23, 2026.

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Feb 19, 2026	Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177	Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177 Thu, Feb 19, 2026 23:33 CET Report this content Stockholm, Sweden, February 19, 2026. Affibody AB (“Affibody”) today announced that a Letter of Intent (LOI) ...
Feb 18, 2026	Affibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement	Affibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement Wed, Feb 18, 2026 14:28 CET Report this content Stockholm, Sweden, February 17, 2026. Affi...
Feb 5, 2026	Intervacc announces change of CEO	Intervacc announces change of CEO Thu, Feb 05, 2026 19:15 CET Report this content The Board of Directors of Intervacc AB (publ), together with Jonas Sohlman, has agreed that he will leave his role as Chief Executive Officer and Group CEO. S...
Jan 20, 2026	Affibody Carries Out Fully Guaranteed Rights Issue of SEK 307 Million	Affibody Carries Out Fully Guaranteed Rights Issue of SEK 307 Million Tue, Jan 20, 2026 10:31 CET Report this content Stockholm, Sweden, January 20, 2026. Affibody Medical AB (publ) (“Affibody”) today announced that the Board of Directors, ...
Dec 16, 2025	Affibody Accelerates Phase 1 Study with ABY-271 Following Initial Patient Data	Affibody Accelerates Phase 1 Study with ABY-271 Following Initial Patient Data Tue, Dec 16, 2025 08:00 CET Report this content Stockholm, Sweden, December 16, 2025. Affibody AB (“Affibody”) today announced that the Trial Review Committee (T...
Jun 18, 2025	The Dawn of Radioligand Therapies: A New Era in Precision Oncology	In the realm of cancer treatment, innovation is the lifeblood that fuels hope. The latest beacon of this hope shines brightly on radioligand therapies (RLTs). These therapies are not just a whisper of potential; they are a clarion call for ...
Jun 16, 2025	Clarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision Oncology	New Report Highlights Emerging Leaders Advancing Next-generation Radiopharmaceuticals, Reshaping Cancer Care Through Targeted Innovation and Strategic Growth LONDON, June 16, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global ...
Jun 4, 2025	Filippa Stenberg joins Mölnlycke Board of Directors	Filippa Stenberg joins Mölnlycke Board of Directors Wed, Jun 04, 2025 08:00 CET Report this content Gothenburg, Sweden. 4 June 2025. Mölnlycke is pleased to announce the election of Filippa Stenberg as a deputy board member to its Board of ...
Aug 14, 2024	Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep	Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep Wed, Aug 14, 2024 08:30 CET Report this content • Phase 3 trial of izokibep in patients with hidradenitis suppurativa met primary endpoi...
Mar 26, 2024	First gastroesophageal cancer patients enrolled in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025	First gastroesophageal cancer patients enrolled in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025 Tue, Mar 26, 2024 09:14 CET Report this content Solna, Sweden, March 26, 2024. Affibody AB (“Affibody”) today announced that ...
Oct 3, 2023	Affibody appoints Peter Zerhouni as CFO	Affibody appoints Peter Zerhouni as CFO Tue, Oct 03, 2023 10:14 CET Report this content Solna, Sweden, October 3, 2023. Affibody AB (“Affibody”) today announced that Peter Zerhouni has been appointed Chief Financial Officer (CFO) of the Com...
Sep 12, 2023	Affibody’s Partner ACELYRIN Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa	Affibody’s Partner ACELYRIN Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa Tue, Sep 12, 2023 08:41 CET Report this content • The primary endpoint of HiSCR75 at w...
Mar 20, 2023	IZOKIBEP PHASE 2B/3 HIDRADENITIS SUPPURATIVA DATA PRESENTED AT THE 2023 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING	IZOKIBEP PHASE 2B/3 HIDRADENITIS SUPPURATIVA DATA PRESENTED AT THE 2023 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING Mon, Mar 20, 2023 08:24 CET Report this content • At 12 weeks, 57% of patients achieved HiSCR75, 38% achieved HiSCR90 and...
Nov 8, 2022	Affibody Announce Positive Additional Izokibep Phase 2 Data in Patients with Psoriatic Arthritis (PsA) will be Presented at American College of Rheumatology (ACR) Convergence 2022	Affibody Announce Positive Additional Izokibep Phase 2 Data in Patients with Psoriatic Arthritis (PsA) will be Presented at American College of Rheumatology (ACR) Convergence 2022 Tue, Nov 08, 2022 17:07 CET Report this content • Izokibep P...
Nov 7, 2022	Affibody’s partner Rallybio Announces Positive Phase 1 Results for RLYB116	Affibody’s partner Rallybio Announces Positive Phase 1 Results for RLYB116 Mon, Nov 07, 2022 22:08 CET Report this content • A single 100 mg subcutaneous dose demonstrated a reduction of >99% in free C5 and was generally well-tolerated. ...
Jun 3, 2022	Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 EULAR Congress	Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 EULAR Congress Fri, Jun 03, 2022 11:15 CET Report this content • Data suggest...
May 3, 2022	Affibody, ACELYRIN, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis	Affibody, ACELYRIN, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Tue, May 03, 2022 16:18 CET Report this content Solna, Sweden, Los Angeles, USA, and Shanghai, China, ...
Jan 12, 2022	Lokon Pharma and Affibody Initiates a Collaboration to Develop Novel Cancer Therapeutics	Lokon Pharma and Affibody Initiates a Collaboration to Develop Novel Cancer Therapeutics Wed, Jan 12, 2022 09:36 CET Uppsala and Solna, Sweden, January 12, 2022. Lokon Pharma AB, a leading biotech company in the area of immunostimulatory ge...
Dec 14, 2021	Affibody AB, ACELYRIN, INC., and Inmagene Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis	Affibody AB, ACELYRIN, INC., and Inmagene Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Tue, Dec 14, 2021 11:03 CET SOLNA, Sweden, LOS ANGELES, Calif., and SHANGHAI, China, Dece...
Nov 16, 2021	Affibody enters agreement with ACELYRIN for the development and commercialization of izokibep at a total deal value of USD 305 million plus royalties	Affibody enters agreement with ACELYRIN for the development and commercialization of izokibep at a total deal value of USD 305 million plus royalties Tue, Nov 16, 2021 15:20 CET Solna, Sweden, November 16, 2021. Affibody AB today announced ...
	Affibody	“Affibody is a Swedish biotech company developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.”